Analysts think Pfizer is fairly priced

Pfizer's stock price seems, partly because of the recent share price losses, to be in line with most of the estimates. Most of the analysts say Pfizer is fairly priced now. Currently the company is being followed by 10 analysts. The average of the current target prices for the stock equals 42,67 USD. This is around 0,46 percent more than the current price of 42,53 USD.

Fair values for Pfizer quite concentrated

For this year Pfizer's revenue will be around 53,61 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 52,55 billion USD.

Historical revenues and results Pfizer plus estimates 2018

The analysts expect for 2018 a net profit of 17,95 billion USD. According to most of the analysts the company will have a profit per share for this book year of 3 USD. The price/earnings-ratio is then 14,18.

Huge dividend Pfizer

For this year the analysts expect a dividend of 1,37 USD per share. The dividend yield is then 3,22 percent. The average dividend yield of the pharmaceutical companies equals a limited 0,5 percent.

Latest estimates around 46 USD

The most recent recommendations for the pharmaceutical company are from Credit Suisse, JP Morgan and Morgan Stanley.

Pfizer's market capitalization is based on the number of outstanding shares around 258,16 billion USD. The Pfizer stock was the past 12 months quite unstable. Since last January the stock is 19 percent higher. This year the stock price moved between 33 and 46 dollar. Since 2008 the stock price is almost 143 percent higher.

Historical stock prices Pfizer

On Friday the stock closed at 42,53 USD.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.